South Korea Patent Allowance for Anti-Obesity Pet Vaccines to Braasch Biotech LLC

Braasch Biotech granted Anti-Obesity patent for pets by Korean Intellectual Property  Office. Commercial utility and novelty for first therapeutic vaccine for use in  obese dogs, cats and horses. Garretson, SD, June 11, 2016 --(PR.com)-- Braasch Biotech LLC,  an emerging biopharmaceutical company pioneering a new field  of anti-somatostatin vaccines, today announced a Notice of Allowance  was received from the South Korean Intellectual Property Office for Braasch’ s patent entitled “Compositions and methods for enhanced somatostatin  immunogenicity.” Working in the area of therapeutic vaccines for  non-infectious conditions, the currently described methods target adult onset obesity. The Patent Allowance provides claims for the therapeutic treatment for  obesity in dogs, cats and horses. The source of obesity includes both  diabetic and non-diabetic causes. The Braasch vaccine technologies,  like other veterinary vaccines, utilize specific immunological responses  post-vaccination. In the case of the Braasch vaccine, the endogenous  hormone somatostatin is targeted. By attenuating the effects  of this counter-regulatory hormone, a therapeutic effect on obesity is realized. “Like human obesity, obesity in dogs and cats is at epidemic proportions.  Although prevention is always the best option, once an animal reaches  the obese state, owner intervention is necessary for the pet’s continued  quality of life and longevity. Currently there are no commercially  available therapeutic treatments for both dogs and cats,” stated  Jeralyn Kay Haffer, CEO and Chairman of Braasch. “We are now  pleased the Korean Intellectual Property Office also has recognized the  vaccine’s novelty and commercial utility in the fight against obesity.” Braasch’s intellectual property portfolio includes multiple patent families  with issued or pending claims directed to utility of anti-somatostatin  vaccine technologies, Somatovac® for multiple metabolic challenges.  These applications relate to both human and veterinary use of the technologies. About Braasch Biotech Braasch Biotech is a biopharmaceutical company with a focus on the  development and commercialization of innovative products of therapeutic  approaches utilizing Somatovac® technologies. Currently in the Product  Pipeline are vaccines for livestock productivity enhancement, increased  fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch  has multiple regulatory submissions in progress on the use of vaccines  in metabolic regulation. Braasch Biotech is a privately held  biopharmaceutical with corporate offices in South Dakota. email info@braaschbiotech.com or visitwww.braaschbiotech.com. Contact Information Jeralyn Kay Haffer CEO and Chairman Tel. 605-376-8752 Fax. 605-594-6256 jeralyn@braaschbiotech.com